跳转至内容
Merck
所有图片(1)

主要文件

查看所有文档

SML2955

Sigma-Aldrich

Mirodenafil dihydrochloride

≥98% (HPLC)

别名:

4-[[3-(5-Ethyl-4,5-dihydro-4-oxo-7-propyl-1H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenyl]sulfonyl]-1-piperazineethanol, dihydrochloride, 5-Ethyl-2-[5-[[4-(2-hydroxyethyl)piperazin-1-yl]sulfonyl]-2-propoxyphenyl]-7-propyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one, dihydrochloride, 5-Ethyl-3,5-dihydro-2-[5-[[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl]-2-propoxyphenyl]-7-propyl-4H-pyrrolo[3,2-d]pyrimidin-4-one, dihydrochloride, SK 3530 dihydrochloride, SK-3530 dihydrochloride, SK3530 dihydrochloride

登录查看公司和协议定价

选择尺寸

10 MG
$113.00
50 MG
$372.00

$113.00

预计发货时间2025年5月22日详情

获取大包装报价
所有图片(1)

选择尺寸

变更视图
10 MG
$113.00
50 MG
$372.00

About This Item

经验公式（希尔记法）:
C26H37N5O5S·2HCl
CAS号:
862189-96-6
分子量:
604.59
MDL號碼:
MFCD28139019
分類程式碼代碼:
12352200
NACRES:
NA.77

$113.00

预计发货时间2025年5月22日详情

获取大包装报价

品質等級

100

化驗

≥98% (HPLC)

形狀

powder

儲存條件

desiccated

顏色

white to beige

溶解度

DMSO: 2 mg/mL, clear

儲存溫度

−20°C

SMILES 字串

[S](=O)(=O)(N4CCN(CC4)CCO)c1cc(c(cc1)OCCC)c2[nH][c](c3[n](cc(c3n2)CCC)CC)=O.Cl.Cl

InChI

1S/C26H37N5O5S.2ClH/c1-4-7-19-18-30(6-3)24-23(19)27-25(28-26(24)33)21-17-20(8-9-22(21)36-16-5-2)37(34,35)31-12-10-29(11-13-31)14-15-32;;/h8-9,17-18,32H,4-7,10-16H2,1-3H3,(H,27,28,33);2*1H

InChI 密鑰

CKPHITUXXABKDL-UHFFFAOYSA-N

生化／生理作用

Mirodenafil (SK3530) is an orally active, highly potent and selective phosphodiesterase-5 (PDE5) inhibitor (IC50 = 338 pM). with therapeutic efficacy in various ED models in vivo. Comparing to sildenafil, mirodenafil shows ~10-times higher PDE5 selectivity in vitro and remains longer in the plasma and corpus cavernosum following oral dosing at 40 mg/kg in rats in vivo.
Orally active, highly potent and selective phosphodiesterase-5 (PDE5) inhibitor with ED therapeutic efficacy in vivo.

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000119244
0000119448
0000106108

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Young H Choi et al.
Biopharmaceutics & drug disposition, 30(6), 305-317 (2009-07-30)
The pharmacokinetics of mirodenafil and its two metabolites, SK3541 and SK3544, after intravenous (5, 10, 20 and 50 mg/kg) and oral (10, 20 and 50 mg/kg) administration of mirodenafil, and the first-pass effect of mirodenafil after intravenous, oral, intraportal, intragastric
Ji Sung Shim et al.
Urology, 91, 244-244 (2016-02-28)
To evaluate the distribution of a daily phosphodiesterase type 5 inhibitor dose (mirodenafil) in rat plasma and bladder and prostate tissue in a model of atherosclerosis-induced chronic pelvic ischemia. Thirty-two 18-week-old male Sprague Dawley rats were divided into two groups.
Ji-Youn Jung et al.
The Journal of veterinary medical science, 70(11), 1199-1204 (2008-12-06)
Mirodenafil (SK3530) is a new potent and selective inhibitor of cGMP-specific phosphodiesterase type 5 (PDE5). Recent clinical trials have demonstrated that mirodenafil is an effective treatment for erectile dysfunction. Its mechanism of action is enhancement of nitric oxide (NO) induced
Hoon Choi et al.
International neurourology journal, 19(1), 19-26 (2015-04-04)
To investigate the protective effect of mirodenafil on bladder function in a rat model of chronic bladder ischemia (CBI). Twenty-four Sprague-Dawley rats were randomized to three groups: untreated, sham-operated rats (control group); untreated, CBI model rats (CBI group); and CBI
Jae Heon Kim et al.
The world journal of men's health, 38(3), 345-352 (2019-08-07)
To validate a novel arteriogenic erectile dysfunction (ED) model with atherosclerosis (AS) based on molecular and histologic evidence induced by chronic pelvic ischemia (CPI) and determine effect of phosphodiesterase-5 inhibitor treatment. Twenty 16-week-old male Sprague-Dawley rats were divided into three
查看所有相关文献

Questions

Reviews

No rating value

Active Filters

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持